Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Kyubo Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6093-1294; OpenAlex author ID A5011410839. Sources: OpenAlex.

Their work

Papers
10 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Survey Study on the Patterns of Practice for Pancreatic Cancer Radiation Therapy in Korea. First author DOI 10.1111/1754-9485.70089↗
  2. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. First author DOI 10.1016/j.ejso.2020.07.029↗
  3. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. Co-author DOI 10.2214/ajr.17.18310↗
  4. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradioth… Last author DOI 10.1007/s10147-017-1129-7↗
  5. Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.4143/crt.2016.336↗
  6. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer. First author PMID 28952226↗
  7. Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. Co-author DOI 10.21873/anticanres.11125↗
  8. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.4143/crt.2015.226↗
  9. Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer-Population-Based Analysis with Propensity Score Matching. First author DOI 10.1007/s11605-015-2941-x↗
  10. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. First author DOI 10.4143/crt.2014.025↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wonguen Jung · 1 shared paper, 2026 · strength 0.63
  2. Eui Kyu Chie · 8 shared papers, 2015–2020 · strength 0.60
  3. Do‐Youn Oh · 7 shared papers, 2015–2020 · strength 0.51
  4. Jin‐Young Jang · 4 shared papers, 2015–2020 · strength 0.29
  5. Yung‐Jue Bang · 4 shared papers, 2015–2017 · strength 0.24
  6. Sung Whan Ha · 4 shared papers, 2015–2016 · strength 0.22
  7. Sun‐Whe Kim · 3 shared papers, 2015–2018 · strength 0.18
  8. Kyung-Hun Lee · 2 shared papers, 2016–2020 · strength 0.16
  9. Seock‐Ah Im · 3 shared papers, 2015–2016 · strength 0.16
  10. Byoung Hyuck Kim · 2 shared papers, 2015–2020 · strength 0.15
  11. Hyeon Kang Koh · 2 shared papers, 2016–2017 · strength 0.14
  12. Ijin Joo · 2 shared papers, 2015–2018 · strength 0.12
  13. Hongbeom Kim · 1 shared paper, 2020 · strength 0.11
  14. Haeryoung Kim · 1 shared paper, 2020 · strength 0.11
  15. Wooil Kwon · 1 shared paper, 2020 · strength 0.11
  16. Kyung Su Kim · 1 shared paper, 2017 · strength 0.10
  17. Eunji Kim · 1 shared paper, 2017 · strength 0.09
  18. Yong Tae Kim · 1 shared paper, 2017 · strength 0.09
  19. Yi‐Jun Kim · 1 shared paper, 2017 · strength 0.08
  20. Dong Ho Lee · 1 shared paper, 2018 · strength 0.08
  21. Su Joa Ahn · 1 shared paper, 2018 · strength 0.08
  22. Jeong Min Lee · 1 shared paper, 2018 · strength 0.08
  23. Ji Kon Ryu · 1 shared paper, 2018 · strength 0.08
  24. Kyoung-Bun Lee · 1 shared paper, 2018 · strength 0.08
  25. Eun Sun Lee · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.